Develops treatments for central nervous system disorders and other chronic diseases using its proprietary drug delivery technology.
Titan Pharmaceuticals, Inc. is a pharmaceutical innovator focused on advancing therapies for chronic diseases through its proprietary ProNeura long-term drug delivery platform. Central to its portfolio is Probuphine, an implant designed for the maintenance treatment of opioid use disorder in stable patients across Canada and the European Union. This technology ensures sustained delivery of medications, offering a reliable alternative to traditional oral treatments.
In addition to Probuphine, Titan Pharmaceuticals is actively developing TP-2021, a kappa opioid agonist peptide program intended to complement the ProNeura platform for managing chronic pruritus. The company is also progressing with its nalmefene implant program, aimed at preventing opioid relapse post-detoxification in patients with opioid use disorder. Furthermore, Titan is exploring innovative applications of ProNeura, including a potential HIV preventative therapeutic and a contraceptive solution from a single implant, addressing specific healthcare needs for women and adolescent girls.
Established in 1992 and headquartered in South San Francisco, California, Titan Pharmaceuticals continues to expand its therapeutic offerings and research capabilities. With a commitment to enhancing patient outcomes through sustained drug delivery technology, Titan remains at the forefront of developing transformative treatments for chronic diseases, underscoring its dedication to innovation and clinical excellence.